Originally Published by Tisento Therapeutics on November 3, 2025.
Findings Demonstrate the Importance of Addressing …
Mitochondrial Disease News
Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY™ (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome
“The approval of FORZINITY, the first treatment option for Barth syndrome and the first approved mitochondria-targeted …
BPGbio Sponsors MitoAction Energy Walk at Boston’s Franklin Park Zoo on September 27th, 2025
Company honored in its commitment to patients and families living with mitochondrial disease; invites the community to …
FDA denies approval for dichloroacetate (DCA), a treatment for Pyruvate Dehydrogenase Complex Deficiency (PDCD).
Earlier today, Saol Therapeutics shared the U.S. Food and Drug Administration (FDA) has issued a Complete Response …
MitoAction Advocates for Barth Syndrome Community in FDA Listening Session
FOR IMMEDIATE RELEASE
[Boston, MA, April 1, 2024] - MitoAction, a leading nonprofit organization dedicated to …
- 1
- 2
- 3
- …
- 27
- Next Page »
